Skip to main content

Relias Media has upgraded our site!

Please bear with us as we work through some issues in order to provide you with a better experience.

Thank you for your patience.

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

December 1, 2022

View Archives Issues

  • Capecitabine Better Than, Not Inferior to, Fluorouracil in Perioperative Treatment of Rectal Cancer

    In a multicenter, Phase 3 trial, perioperative chemoradiotherapy with capecitabine proved safe and equivalently effective as fluorouracil in reducing local recurrence. In fact, post hoc analysis demonstrated better disease-free and overall survival for those treated with capecitabine. This is a finding that will resonate in the offices of community-based oncologists.
  • PET/CT as Tool in Assessing Response to Neoadjuvant CRT for Rectal Cancer

    Neoadjuvant chemoradiotherapy has become the standard approach for patients with locally advanced rectal adenocarcinoma. For patients who achieve a complete response determined preoperatively, less than maximally aggressive surgery has been contemplated. However, improved accuracy of the preoperative assessment needs to be established. In the current prospective evaluation, assessments of response were made with and without the use of PET/CT in a consecutive series and it was found that the additional scans were useful adjuncts to comprehensive clinical examination.
  • Transarterial Chemoembolization ± Intravenous Bevacizumab in the Treatment of Hepatocellular Cancer

    In this single-institute pilot study, 30 subjects with hepatocellular cancer were randomized to transarterial chemoembolization with or without bevacizumab. Bevacizumab use significantly improved progression-free survival at 16 weeks but no significant difference was seen with respect to the primary outcome (vessel count) or in the overall survival.
  • Waldenström Macroglobulinemia with Hyperviscosity

    A 57-year-old retail pharmacist presented to his primary care physician because of progressive headaches, blurry vision, hearing loss, and episodes of confusion. He had not had night sweats, fever, or weight loss. On physical examination he was found to be pale and there were ecchymoses over his upper and lower extremities that he reported occurred spontaneously over the past 3 months. He had attributed these to his current medications including both aspirin (81 mg/day) and clopidogrel (75 mg/day), although he had been taking these medications for more than 5 years without noticing ecchymoses in the past. He did not have palpable lymphadenopathy nor was there splenomegaly.
  • No 'Go' with CoQ10 for Treatment-Related Fatigue

    Results of this well-done trial strongly suggest that CoQ10 administration over 24 weeks' time does not help relieve the treatment-related fatigue experienced by a significant proportion of women with newly diagnosed breast cancer.
  • Pharmacology Watch: FDA Approves First New Anti-Obesity Drug in Years

    Lorcaserin for weight loss; statins and fatigue; treatment-resistant gonorrhea; hydrocodone classification changes; USPSTF recommendations; and FDA actions.
  • Clinical Briefs in Primary Care Supplement